138 related articles for article (PubMed ID: 34299796)
1. The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border.
Grant AH; Ayala-Marin YM; Mohl JE; Robles-Escajeda E; Rodriguez G; Dutil J; Kirken RA
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299796
[TBL] [Abstract][Full Text] [Related]
2. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
[TBL] [Abstract][Full Text] [Related]
3. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.
Lindquist KE; Karlsson A; Levéen P; Brunnström H; Reuterswärd C; Holm K; Jönsson M; Annersten K; Rosengren F; Jirström K; Kosieradzki J; Ek L; Borg Å; Planck M; Jönsson G; Staaf J
Oncotarget; 2017 May; 8(21):34796-34810. PubMed ID: 28415793
[TBL] [Abstract][Full Text] [Related]
4. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Husemann P; Krell PF; Borkhardt A; Dugas M; Hu J; Fischer U
Leuk Res; 2015 Sep; 39(9):990-1001. PubMed ID: 26189108
[TBL] [Abstract][Full Text] [Related]
5. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
6. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
7. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
Zugazagoitia J; Rueda D; Carrizo N; Enguita AB; Gómez-Sánchez D; Díaz-Serrano A; Jiménez E; Mérida A; Calero R; Lujan R; De Miguel E; Gámez P; Díaz-Hellín V; Nuñez JA; Iglesias L; Ferrer I; Paz-Ares L; Ponce-Aix S
Clin Lung Cancer; 2018 Jan; 19(1):65-73.e7. PubMed ID: 28780976
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
9. Recurrent chromosomal rearrangements of
Bayard Q; Caruso S; Couchy G; Rebouissou S; Bioulac Sage P; Balabaud C; Paradis V; Sturm N; de Muret A; Guettier C; Bonsang B; Copie C; Letouzé E; Calderaro J; Imbeaud S; Nault JC; Zucman-Rossi J
Gut; 2020 Sep; 69(9):1667-1676. PubMed ID: 31907296
[TBL] [Abstract][Full Text] [Related]
10. Quadruple and Truncated MEK3 Mutants Identified from Acute Lymphoblastic Leukemia Promote Degradation and Enhance Proliferation.
Ayala-Marin YM; Grant AH; Rodriguez G; Kirken RA
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830095
[TBL] [Abstract][Full Text] [Related]
11. Spectrum of gene mutations identified by targeted next-generation sequencing in Chinese leukemia patients.
Yao H; Wu C; Chen Y; Guo L; Chen W; Pan Y; Fu X; Wang G; Ding Y
Mol Genet Genomic Med; 2020 Sep; 8(9):e1369. PubMed ID: 32638549
[TBL] [Abstract][Full Text] [Related]
12. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
13. Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
Dong D; Shen G; Da Y; Zhou M; Yang G; Yuan M; Chen R
Oncologist; 2020 Nov; 25(11):e1720-e1724. PubMed ID: 32652753
[TBL] [Abstract][Full Text] [Related]
14. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
15. Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program.
Vashistha V; Armstrong J; Winski D; Poonnen PJ; Hintze B; Price M; Snowdon JL; Weeraratne D; Brotman D; Jackson GP; Kelley MJ
JCO Oncol Pract; 2021 Jul; 17(7):e1012-e1020. PubMed ID: 33780286
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing in Acute Lymphoblastic Leukemia.
Coccaro N; Anelli L; Zagaria A; Specchia G; Albano F
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208040
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
Huang RSP; Haberberger J; Sokol E; Schrock AB; Danziger N; Madison R; Trabucco S; Jin D; Pavlick D; Ramanan V; Hole K; McGregor K; Venstrom J; Ross JS
Int J Cancer; 2021 Apr; 148(7):1778-1788. PubMed ID: 33336398
[TBL] [Abstract][Full Text] [Related]
18. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management.
Bierzynska A; McCarthy HJ; Soderquest K; Sen ES; Colby E; Ding WY; Nabhan MM; Kerecuk L; Hegde S; Hughes D; Marks S; Feather S; Jones C; Webb NJ; Ognjanovic M; Christian M; Gilbert RD; Sinha MD; Lord GM; Simpson M; Koziell AB; Welsh GI; Saleem MA
Kidney Int; 2017 Apr; 91(4):937-947. PubMed ID: 28117080
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
20. Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.
Messina M; Chiaretti S; Wang J; Fedullo AL; Peragine N; Gianfelici V; Piciocchi A; Brugnoletti F; Di Giacomo F; Pauselli S; Holmes AB; Puzzolo MC; Ceglie G; Apicella V; Mancini M; Te Kronnie G; Testi AM; Vitale A; Vignetti M; Guarini A; Rabadan R; Foà R
Oncotarget; 2016 Mar; 7(12):13886-901. PubMed ID: 26883104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
